Ubs Group Ag Cel Sci Corp Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Cel Sci Corp stock. As of the latest transaction made, Ubs Group Ag holds 92,280 shares of CVM stock, worth $220,549. This represents 0.0% of its overall portfolio holdings.

Number of Shares

92,280

Previous 97,089 4.95%

Holding current value

$220,549

Previous $38,000 44.74%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$0.23 - $0.45 $1,106 - $2,164	-4,809 Reduced 4.95%	92,280 $21,000
Q4 2024 Feb 14, 2025	BUY	$0.4 - $1.11 $20,695 - $57,430	51,739 Added 114.09%	97,089 $38,000
Q3 2024 Nov 14, 2024	SELL	$1.05 - $1.5 $79,853 - $114,076	-76,051 Reduced 62.64%	45,350 $48,000
Q2 2024 Aug 13, 2024	BUY	$1.11 - $1.85 $76,681 - $127,801	69,082 Added 132.04%	121,401 $140,000
Q1 2024 May 13, 2024	BUY	$1.63 - $3.08 $48,909 - $92,418	30,006 Added 134.48%	52,319 $99,000
Q4 2023 Feb 09, 2024	BUY	$1.07 - $3.07 $6,913 - $19,835	6,461 Added 40.76%	22,313 $60,000
Q3 2023 Nov 09, 2023	BUY	$1.17 - $2.86 $905 - $2,213	774 Added 5.13%	15,852 $19,000
Q2 2023 Aug 11, 2023	BUY	$2.11 - $2.83 $2,266 - $3,039	1,074 Added 7.67%	15,078 $36,000
Q1 2023 May 12, 2023	SELL	$2.17 - $3.13 $16,442 - $23,716	-7,577 Reduced 35.11%	14,004 $32,000
Q4 2022 Feb 08, 2023	BUY	$1.99 - $3.52 $28,329 - $50,110	14,236 Added 193.82%	21,581 $50,000
Q3 2022 Nov 10, 2022	BUY	$3.09 - $5.23 $7,252 - $12,274	2,347 Added 46.96%	7,345 $22,000
Q2 2022 Aug 10, 2022	SELL	$2.58 - $4.99 $3,062 - $5,923	-1,187 Reduced 19.19%	4,998 $23,000
Q1 2022 May 16, 2022	SELL	$3.93 - $7.7 $829,835 - $1.63 Million	-211,154 Reduced 97.15%	6,185 $24,000
Q4 2021 Feb 14, 2022	SELL	$7.1 - $12.82 $102,218 - $184,569	-14,397 Reduced 6.21%	217,339 $1.54 Million
Q3 2021 Nov 15, 2021	BUY	$7.64 - $12.49 $1.58 Million - $2.58 Million	206,213 Added 807.95%	231,736 $2.55 Million
Q2 2021 Aug 13, 2021	SELL	$8.68 - $27.49 $520,253 - $1.65 Million	-59,937 Reduced 70.13%	25,523 $221,000
Q1 2021 May 12, 2021	BUY	$12.0 - $27.64 $918,012 - $2.11 Million	76,501 Added 853.9%	85,460 $1.3 Million
Q4 2020 Feb 11, 2021	BUY	$11.05 - $16.62 $34,851 - $52,419	3,154 Added 54.33%	8,959 $105,000
Q3 2020 Nov 12, 2020	SELL	$11.69 - $14.54 $506,609 - $630,119	-43,337 Reduced 88.19%	5,805 $74,000
Q2 2020 Jul 31, 2020	BUY	$9.75 - $17.6 $279,074 - $503,764	28,623 Added 139.5%	49,142 $733,000
Q1 2020 May 01, 2020	SELL	$7.54 - $17.05 $111,456 - $252,033	-14,782 Reduced 41.87%	20,519 $237,000
Q4 2019 Feb 14, 2020	BUY	$6.71 - $9.55 $161,831 - $230,326	24,118 Added 215.67%	35,301 $323,000
Q3 2019 Nov 14, 2019	BUY	$6.0 - $9.6 $44,706 - $71,529	7,451 Added 199.65%	11,183 $100,000
Q2 2019 Aug 14, 2019	SELL	$3.77 - $8.67 $6,141 - $14,123	-1,629 Reduced 30.39%	3,732 $32,000
Q1 2019 May 14, 2019	BUY	$2.58 - $3.54 $10,559 - $14,489	4,093 Added 322.79%	5,361 $19,000
Q3 2018 Nov 14, 2018	BUY	$0.83 - $4.16 $803 - $4,026	968 Added 322.67%	1,268 $5,000
Q1 2018 May 15, 2018	BUY	$1.38 - $2.33 $20 - $34	15 Added 5.26%	300 $0
Q2 2017 Aug 14, 2017	BUY	N/A	285	285 $1,000

Others Institutions Holding CVM

# of Institutions

Shares Held

7.55M

Call Options Held

73.8K

Put Options Held

106K

View Full List

About CEL SCI CORP

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $104M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

More about CVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account